Metastatic castration-resistant prostate cancer with BRCA mutation

Metastatic castration-resistant prostate cancer with BRCA mutation is an advanced, lethal malignancy of the male genitourinary system in which prostate adenocarcinoma has disseminated to distant sites—most commonly bone, lymph nodes, or viscera—and continues to progress despite medical or surgical castration levels of serum testosterone The condition is specifically characterized by deleterious germline or somatic mutations in the *BRCA1* or *BRCA2* tumor suppressor genes, which impair homologou...

Metastatic castration-resistant prostate cancer with BRCA mutation is an advanced, lethal malignancy of the male genitourinary system in which prostate adenocarcinoma has disseminated to distant sites—most commonly bone, lymph nodes, or viscera—and continues to progress despite medical or surgical castration levels of serum testosterone

The condition is specifically characterized by deleterious germline or somatic mutations in the *BRCA1* or *BRCA2* tumor suppressor genes, which impair homologous recombination repair of DNA double-strand breaks

This genomic defect leads to marked genomic instability, aggressive tumor biology, and a distinctive therapeutic vulnerability to synthetic lethality mediated by poly(ADP-ribose) polymerase (PARP) inhibitors